The Supreme Court has asked the government to justify why drug price controls are limited primarily to anti-cancer medications. The court flagged massive markups on essential medicines, signaling a potential for wider price oversight. Investors are assessing this, as any extension of price caps could impact the revenue and profit margins of retail pharmacy chains and hospital-linked pharmacies.
The Supreme Court has initiated a critical review of the government’s drug pricing policy, questioning why strict price controls and trade margin caps are currently restricted to anti-cancer medications. During the proceedings, the bench, comprising Justices Vikram Nath and Sandeep Mehta, asked the government to explain the logic behind this limited scope when other essential medicines continue to remain outside similar price oversight. The court highlighted concerns over the significant gap between the Price to Retailer (PTR) and the Maximum Retail Price (MRP), noting that this disparity often leads to excessive costs for patients.
For investors, the core issue lies in the business model of the Indian pharmaceutical retail sector. Many large hospital chains and standalone pharmacy retail networks generate a portion of their income from the trade margins on non-scheduled drugs. Currently, these drugs can have wider price variations compared to 'scheduled' medicines, which are already regulated under the Drug Price Control Order (DPCO) 2013 with fixed retail margins, often around 16%. The government’s recent decision to cap trade margins for non-scheduled anti-cancer drugs at 30% was a targeted intervention, but the Court’s query suggests a move toward a more uniform or broader regulatory approach.
The potential risk for shareholders is margin compression. If the government follows the Court’s line of reasoning and expands these price caps to a wider basket of essential drugs, it would directly impact the pharmacy revenue models of corporate hospitals and retail chains. These businesses rely on higher margins from these drugs to offset operating costs. Any move to enforce a lower, uniform markup across all essential medicines could lead to lower profits in the pharmacy segment, which has been a key growth area for many healthcare companies.
Sector performance has already reflected some of this regulatory uncertainty, with pharmacy and hospital-linked stocks experiencing increased volatility recently. While the government argued that intervention must be balanced to avoid disrupting supply chains, the Court has signaled that the current pricing freedom enjoyed by manufacturers and retailers is under intense scrutiny. The court has directed the government to form a committee to examine marketing practices and pricing frameworks. The next hearing is expected to provide further clarity, and the industry is awaiting details on whether a broader price control mandate will be implemented, which remains a key monitorable for the sector’s financial outlook.